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Abstract 
Niemann-Pick disease type C is a rare lipid trafficking disorder characterized by the 
accumulation of cholesterol and glycosphingolipids in the brain and viscera. Perinatal, early 
infantile, late infantile, juvenile and adult forms are distinguished based on the age of 
manifestation. In the juvenile form, patients in their early years are usually, but not always, 
symptom free but present with neurodegeneration later in their lives. These include 
clumsiness, ataxia, seizures, motor and intellectual decline. Psychiatric manifestations may 
occur at any stage of the disease. These manifestations include schizophrenia, presenile 
dementia, depression or psychosis. In 2009, miglustat was approved for the therapy of the 
disease. We present a case of a patient with juvenile Niemann-Pick C whose psychosis was 
reversed, completely, by miglustat treatment. Based on our clinical experience we encourage 
the introduction of misgulustat in Niemann-Pick C patients even in the most advanced cases, 
with respect to psychiatric illness. 
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Introduction 
Niemann-Pick disease type C (NPC, OMIM 257220) is a rare lysosomal storage disease 
characterized by a defect in lipid trafficking within organelles. This is primarily due to the 
impaired functions of the NPC1 or NCP2 proteins. Several types of lipids including 
unesterified free cholesterol, sphingosine, sphingomyelin, phospholipids and 
glycosphingolipids accumulate in the lysosomes and late endosomes,
1
 resulting in 
organomegaly, impaired liver function and progressive neurological damage. Neurological 
symptoms may include psychomotor retardation, clumsiness, ataxia, dysphagia, dysarthria, 
presenile dementia and vertical supranuclear gaze palsy. Psychiatric manifestations are often 
reported in adolescent and adult patients.
2
 In general, the age of onset of neurological signs 
inversely correlates with progression rates. In the juvenile and adult onset forms, psychomotor 
development is usually normal in the early ages, but a gradual loss of previously acquired 
skills may suggest the underlying neurometabolic disease. It seems that visceral symptoms 
decrease and neuropsychiatric symptoms emerge with advancing age.
3
 There is no causative 
therapy for NPC – slowing disease progression is the most promising option. In 2009, 
miglustat (Zavesca, Actelion Pharmaceuticals, Allschwil, Switzerland) was approved by 
European Union countries as the only specific therapy of the disease. The mechanism of 
action includes the inhibition of glycosphingolipid synthesis, thus reducing the accumulation 
of storage material in NPC1 deficient cells, resulting in partial improvement or stabilization of 
neurological symptoms. The latest guidelines recommend the initiation of miglustat following 
the appearance of neurological symptoms.
4
 However, the extreme heterogeneity of the 
disease, the subtle clinical symptoms may hinder its recognition and severely delay the 
initiation of adequate therapy. Several cases presenting with psychosis and schizophrenia-like 
symptoms remain undetected.
5
 In this paper, the authors present a case of a young adult 
patient with juvenile onset NPC who suffered from a severe psychotic episode but fully 
recovered following miglustat therapy.  
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Case Study 
Patient (male) was born from unrelated, healthy Caucasian parents. He has a healthy older 
sister. The perinatal and infantile period was uneventful. No prolonged neonatal jaundice was 
noted. Psychomotor development was normal until adolescence, although attention deficit and 
delayed reactions to environmental stimuli was reported since preschool age. Involuntary 
torsion-like movements of the arms were first noted at 10 years of age but were misjudged as 
a bad habit or tick. At age 14, a consultation with a pediatric neurologist took place due to 
symptoms such as slurred speech and coordination problems. The parents reported frequent 
falls and loss of balance. On physical examination, slight swaying to the right in Romberg’s 
test and right deviation of the tongue was described. Audiological examination revealed 
central hypacusis at high frequencies. Brain MRI was normal. Later, dyslexia and dysgraphia 
developed, but the patient fulfilled the normal curriculum with satisfactory grades until he 
was 17 years old. A pediatric psychologist estimated his intellect to be normal, with verbal 
performance in the average range and motor performance slightly below average. Fine motor 
skills started to decline more rapidly at age 17, and dysphagia developed. A repeated 
neurological examination disclosed mild central facial paresis, diminished pharyngeal 
reflexes, dysarthria, subjective dysphagia, mild cerebellar ataxia, dystonia of the hands and 
fingers and vertical supranuclear gaze palsy when looking downwards. The possibility of a 
neurodegenerative disease was raised, but a repeated MRI showed no abnormality (Fig. A). 
However, brain-stem auditory evoked potentials signalled diffuse brain stem dysfunction. 
Abdominal ultrasonography showed isolated splenomegaly, the estimated volume of the 
spleen was 440 mL, which, together with the vertical supranuclear gaze palsy and the gradual 
decline of motor skills suggested Niemann-Pick C disease. A bone marrow biopsy was 
performed and confirmed the presence of CD68 positive foamy macrophages, also staining 
positive with Oil Red O. Fibroblast filipin staining was performed at the Mayo Clinic, 
Rochester, MN, USA according to standard protocol but it could not confirm and neither rule 
out NPC, cholesterol esterification rate was 17% of the normal control but higher than in 
control NPC-deficient fibroblasts. For mutation analysis, NPC1 exons were individually 
amplified and sequenced. Compound heterozygous missense mutations in the NPC1 gene 
were found: c.3019 C>G mutation in exon 20 (p. Pro1007Ala), and c.3182 T>C in exon 21 (p. 
Ile1061Thr) resulting in the genotype of [c.3019 C>G] + [c.3182 T>C] (Fig. D). Both 
mutations were described previously in the literature, their pathogenicity is proven.
6,7
 Testing 
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of the parents' sample revealed that the c.3019 C>G mutation was inherited from the mother 
while the c.3182 T>C mutation from the father. At age 20.5 years remarkable cognitive and 
behavioral changes occurred: visual hallucinations, paranoid thoughts and distortion of the 
reality caused the parents to seek medical help for their child. He lost ability of spatial 
orientation and reacted inadequately in everyday situations. Attention span was reduced. 
MMSE was 30/23 suggesting dementia and cognitive decline. Over the next four weeks, 
persecutory delusions, sleep disturbance, anxiety, bizarre paranoid doxasmas developed, for 
which psychiatric inpatient care was needed. Olanzapine 10mg/die and clonazepam 2mg/die 
(0.5-0.5-1mg) were introduced. Brain MRI at this time showed moderate degree diffuse 
cerebral atrophy (Fig. B). IQ could not be measured because of incoherent thinking. After two 
weeks of ineffectiveness, the dose of olanzapine was increased to 20mg/die, the maximum 
adult dose, and that of clonazepam was reduced to 0.5mg/die. Seeing no improvement of 
symptoms after another two weeks of modified therapy, both drugs were gradually omitted 
and fisrt-generation haloperidol (3x1.5mg) was introduced. This resulted in little partial 
improvement, but with respect to his best achievable status, the patient was exmitted from 
hospital (10 weeks from the onset of psychotic symptoms). Haloperidol was maintained in a 
dose of 2x2.5mg/die. However, only 5 weeks later a dystonic crisis appeared, and haloperidol 
had to me omitted. We tried aripiprazole, another first-generation antipsychotic known to 
provoke fewer extrapyramidal side effects, yet the movement disorder was so severe that 
aripiprazole could not be continued. The dystonic storm was successfully treated with 
intravenous diazepam and biperiden, carbamazepine suppository and oral baclofen. Right 
after the approval of the drug in Hungary (six weeks from the onset of psychotic symptoms), 
miglustat was introduced in a dose of 3x200 mg per day, and was given strictly troughout the 
course of the psychotic disease independent from other medications. Its side effect was 
temporary diarrhoea resolving spontaneously after six months of therapy. Three months after 
the initiation of miglustat and two weeks after cessation of all antipsychotics from necessity in 
a non-symptom-free psychiatric status, psychotic symptoms gradually resolved and did not 
recur ever since. Brain MRI performed at age 22 and also at 23 years showed no progression 
of cerebral atrophy (Fig. C). At age 23 years, after 3 years of follow-up, the patient had an 
overall IQ of 79, certain skills were more severely affected than others: verbal intelligence 
was in average range (VQ=92), performance intelligence reflected mild mental subnormality 
(PQ=68). MMSE is 30/26. He recognized social and moral norms above average level, logical 
thinking, reasoning, mathematical skills and visuomotor coordination were severely impaired. 
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At present, by age 24 years, this fairly good psychomotor status is still preserved. He requires 
round the clock supervision by his parents but remained ambulatory, capable of self-care and 
does sports on an everyday basis. No signs of psychosis has reappeared in the past 4 years.  
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Discussion 
Neuropsychiatric manifestations of Niemann-Pick C disease may occur at any stage of the 
disease and are most likely to define clinical outcome over other symptoms. Apart from early 
dementia and cognitive decline, schizophrenia, depression or psychosis are often reported, 
especially in adolescent and adult patients.
2
 Recently, an NPC suspicion index was developed 
to help professionals enhance the early recognition of the disease.
8
 Reducing time interval 
between the onset of symtoms and the definitive diagnosis appears to be of paramount 
importance. Emerging treatments should be more efficient at the visceral or 
cognitive/psychiatric stages of the disease, before the occurrence of widespread deep brain 
neurological lesions.
9,10
 In 2009, miglustat was approved as the only specific therapy of NPC 
and was found to achieve stabilization or partial improvement of neurological symptoms. 
According to the recommendations of the NPC Guidelines Working Group, patients without 
neurological manifestations should not receive miglustat as some can remain asymptomatic 
for a considerable period of time. In cases where severe neurological impairment is already 
present at the time of diagnosis, particularly in very young patients, miglustat is less likely to 
provide substantial therapeutic benefits.
11
 To date, a number of clinical research focus on the 
beneficial therapeutic effect of miglustat upon the neurological manifestations of the disease, 
but only a few deal with its favourable influence upon psychiatric symptoms, social behaviour 
and quality of life from the patients’ and caregivers’ perspectives.5 Here we presented a case 
of a patient with juvenile-onset NPC who suffered from a severe psychotic episode that 
resisted to all administered antipsychotic medications but was ameliorated by miglustat within 
three months, and a fairly good quality of life was regained. Our conviction that miglustat is 
responsible for such an improvement of psychiatric symptoms is supported by the observation 
that improvement occurred when no conventional antipsychotics could be given due to severe 
dystonia and miglustat was the only medication the patient received apart from oral 
anticholinergic pyridostigmin as long as the dystonic crisis lasted, and that psychotic 
symptoms have not recurred in 3 years of follow up. We also aim to point out that vertical 
supranuclear gaze palsy, isolated splenomegaly, bulbar signs and gradual psychomotor 
decline of a previously symptom-free young patient were key features suggesting Niemann-
Pick C, and providing a basis for clinical and molecular diagnosis. In patients where 
psychiatric symptoms occur earlier than the knowledge of the underlying metabolic disease is 
gained, there is a greater chance that physicians focus on treating the mental illness and miss 
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important signal signs that could indicate its organic origin and direct health care 
professionals to initiate a specific – although not curative – therapy. Based on our clinical 
experience we suggest a careful revision of the anamnesis and checking for vertical 
supranuclear gaze palsy and bulbar symptoms such as difficulties in swallowing and 
articulation in all patients with schizophrenia and psychosis, and encourage the introduction 
of miglustat to NPC patients even in a more advanced stage of psychiatric illness.  
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Figure legend 
 
T2 weighted axial images performed at age 17 (A), 20.5 (B), and 23 (C) years. At age 17 no 
signs of atrophy can be detected, while moderate degree atrophy developed between ages 17-
20.5 years (A and B). Between ages 20.5 and 23, closely from the introduction of miglustat 
therapy, atrophy showed no progress. Electropherogram of patient showing compound 
heterozygote mutations c.3019 C>G in exon 20, (p. P1007A), and c.3182 T>C in exon 21 (p. 
I1061T) (D).  
 
 
 
